Amryt Pharma focuses on the developing and delivering new treatments to help improve the lives of patients with rare and orphan diseases. Read more
Amryt Pharma focuses on the developing and delivering new treatments to help improve the lives of patients with rare and orphan diseases. Read more
Co-Founder & CEO
Joseph Wiley
AOP Orphan is Amryt Pharma's #1 competitor. AOP Orphan's headquarters is in Vienna, Vienna, and was founded in 1996. AOP Orphan competes in the industry. AOP Orphan generates 63% of Amryt Pharma's revenue.
Annual Revenue
$100M
Amryt Pharma's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 44.3M. Over the last two quarters, Amryt Pharma's revenue has grown by 3.6%. Specifically, in Q2 2020's revenue was $46.2M; in Q1 2020, it was $44.6M.
These are all the companies that Amryt Pharma has acquired. Amryt Pharma's latest acquisition was Aegerion Pharmaceuticals, Inc. in May 2019. Aegerion develops and commercializes novel therapies for patients with rare diseases.
Since Amryt Pharma was founded in 2015, it has participated in 2 rounds of funding. In total Amryt Pharma has raised $30.8M. Amryt Pharma's last funding round was on Dec 2018 for a total of $9.6M
Since Amryt Pharma was founded in 2015, it has participated in 2 rounds of funding. In total Amryt Pharma has raised $30.8M. Amryt Pharma's last funding round was on Dec 2018 for a total of $9.6M
No recent investments found related to Amryt Pharma
These are all the companies that Amryt Pharma has invested in. Amryt Pharma's latest investment was Aegerion Pharmaceuticals, Inc. in May 2019. Aegerion develops and commercializes novel therapies for patients with rare diseases.
